MedTrace Logo

Pioglitazone for Idiopathic Gastroparesis

NCT04300127 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-04-30

Study results available
· View outcomes & findings →

Summary

The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.

Conditions

Interventions

DRUG

Pioglitazone 30 mg

Patients will received 30 mg of Pioglitazone once a day for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Glenn J Treisman, MD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-24
Primary Completion
2025-03-15
Completion
2025-03-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04300127 on ClinicalTrials.gov